1/21
Vocabulary practice flashcards covering goal-directed medical therapy, ACC/AHA stages, NYHA functional classes, ejection fraction categories, and pharmacology for heart failure.
Goals of Heart Failure Treatment
The three overarching clinical objectives: improving symptoms to maintain functional capabilities and quality of life, reducing hospitalizations, and improving overall survival.
Goal Directed Medical Therapy (GDMT)
An evidence-based medication regimen recommended by clinical guidelines for outpatient heart failure management, primarily selected according to left ventricular ejection fraction.
The Four Pillars of GDMT
The four medication classes proven to reduce morbidity and mortality in heart failure with reduced ejection fraction: ARNIs (or ACE inhibitors/ARBs), beta blockers, mineralocorticoid receptor antagonists (MRAs), and SGLT2 inhibitors.
Heart Failure Phenotype
The observable clinical pattern and presentation of a patient based on ejection fraction, cardiac function, cardiac structure, and associated comorbidities.
ACC/AHA Stage A
Patients who are at risk for heart failure but have not yet developed structural heart disease or symptoms of heart failure.
ACC/AHA Stage B
Pre-heart failure defined by the presence of structural heart disease without any prior or current symptoms of heart failure.
ACC/AHA Stage C
Established heart failure characterized by structural heart disease with current or prior symptoms.
ACC/AHA Stage D
Advanced heart failure characterized by refractory symptoms that interfere with daily life and require advanced interventions such as LVAD placement, heart transplantation, or hospice care.
NYHA Functional Class I
A classification where cardiac disease causes no limitation of physical activity; ordinary physical activity does not induce symptoms.
NYHA Functional Class II
Slight limitation of physical activity where patients are comfortable at rest, but ordinary physical activities (such as walking outside or walking around a mall) cause fatigue or dyspnea.
NYHA Functional Class III
Marked limitation of physical activity where symptoms occur with less-than-ordinary activity and interfere with basic activities of daily living such as brushing teeth, cooking, or climbing stairs.
NYHA Functional Class IV
Inability to carry out any physical activity without discomfort, with symptoms of heart failure present even at rest.
Heart Failure with Reduced Ejection Fraction (HFrEF)
Heart failure characterized by an ejection fraction of 40% or less, resulting from systolic pump failure that requires quadruple therapy under GDMT.
SGLT2 Inhibitors in Heart Failure
The sole drug class recommended across all ejection fraction ranges (reduced, mildly reduced, and preserved) that decreases hospitalizations through osmotic and natriuretic diuresis.
Hydralazine plus Isosorbide Dinitrate
A vasodilator combination that lowers preload and afterload; used as an alternative for patients unable to tolerate ACE inhibitors/ARBs/ARNIs, or added to improve morbidity and mortality in persistently symptomatic African American patients with NYHA Class III or IV heart failure.
Loop Diuretics (e.g., Furosemide / Lasix, Bumetanide / Bumex)
Workhorse agents that promote rapid elimination of salt and water from the loop of Henle to treat fluid overload and symptoms, with no effect on morbidity or mortality.
Aldosterone Receptor Antagonists / MRAs
Potassium-sparing agents (such as spironolactone and eplerenone) that block aldosterone in the collecting duct to reduce cardiac remodeling and fluid retention while preventing hypokalemia.
Venous Capacitance
The storage volume capacity of the venous vascular bed; expanding this capacity through venodilators decreases ventricular preload by preventing excessive volume return to the heart.
Evidence-Based Beta Blockers for Heart Failure
The only three beta blockers proven in trials to reduce mortality in heart failure: carvedilol, bisoprolol, and metoprolol succinate (specifically excluding metoprolol tartrate).
Digoxin
An inotropic drug that inhibits the sodium-potassium ATPase pump to increase intracellular calcium and contractility while slowing SA/AV node conduction; used for symptom control and atrial fibrillation, but has a narrow therapeutic window and no mortality benefit.
Dobutamine
A short-term intravenous beta-1 receptor agonist that increases myocardial contractility and cardiac output in patients with acute exacerbations or advanced decompensation.
Milrinone
An intravenous bipyridine inotropic agent typically administered as a continuous infusion to manage refractory end-stage heart failure or serve as a bridge to heart transplantation or an LVAD.